An investigation for investors in NASDAQ:RPTP shares was announced concerning the buyout of Raptor Pharmaceutical Corp. by Horizon Pharma plc for $9.00 per share
Investors who purchased shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) and currently hold any of those NASDAQ:RPTP shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Raptor Pharmaceutical directors breached their fiduciary duties owed toNASDAQ:RPTP investors in connection with the proposed acquisition.
On September 12, 2016, Horizon Pharma plc and Raptor Pharmaceutical Corp. announced the companies have entered into an agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) common stock for $9.00 per share in cash, for an implied fully diluted equity value of approximately $800 million.
However, given that at least one analyst has set the high target price for NASDAQ:RPTP shares at $11.00 per share and given that NASDAQ:RPTP shares reached as high as $16.00 per share in June 2015, the investigation concerns whether the offer is unfair to(NASDAQ:RPTP stockholders. More specifically, the investigation concerns whether the Raptor Pharmaceutical Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
Those who are current investors in NASDAQ:RPTP shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego